MarketFoolery Transcripts

And a look at other questions investors might have.

Regeneron Pharmaceuticals stock got a shot in the arm after it announced a possible drug candidate for coronavirus.

How ignoring your instincts now could lead to a better financial outcome in the long run.

And should they be on your watch list?

It's time for another round of "Yes, No, Maybe So."

The young streaming-video leader outgrew its subscriber forecast last quarter, while the old tech giant slipped back into revenue shrinkage mode.

That’s about how many net new subscribers the streaming service added last quarter, which blew analysts' estimates and its own guidance out of the water.

Shares sank to a 52-week low after a quarterly report that showed the tech pioneer was back in contraction mode.

Listener Jason is looking for resources that will give insight into what businesses see as their key initiatives.

Earnings, new deals, surprising news, and more.

We bring you three stock picks from north of the border. Also, find out which company is called the Berkshire Hathaway of Canada.

If you want to invest in things you understand, drug developers are likely a poor choice.

The Motley Fool’s chief investment officer shares who and what he’s watching this year.

Its stock has grown 900% in a decade, and the company just beat market expectations and substantially raised its guidance.

The restaurant's slide was way out of proportion to its earnings miss. The automaker's wiggle reflects trust issues.

Moderna shares got a boost as the company continued its COVID-19 vaccine trials.

Down 40% overnight, GameStop desperately needs to shake it up to survive in a more digital world.

Tiffany and Lands’ End report OK quarters on OK years, and the story just doesn’t seem to be improving.

Tilray is taking over its majority stakeholder. Welcome to downstream merger Monday, and be glad if you’re a Tilray shareholder.

Zoom's management has big plans for the company, and its latest acquisition is part of them.